Replies to post #40109 on Biotech Values

[cristrader]

MCU Medicure
@donotknowityet/drbio45

MCU will be able to fund the Phase III MEND-CABG II study through to completion without a partnership but that should be the last option.

A partnership is absolutly necessary to start their phase 3 trials in MC-4232 and MC-1 for ACS. Does Medicure want to wait further 18-20 months with the advancement of these programs? I think not, that´s not acceptable!



Latest presentation:
http://library.corporate-ir.net/library/10/108/108925/items/221863/MedicureNov17-FourSeasonsFINAL.pd...

[donotknowityet]

mcu medicure

Drbio,

The important issue you raise is that Medicaure has a rich pipeline. Currently the company has enough money to complete MC-1 for CABG, but no money to move forward the rest of the pipeline.

If they find the right way to finance those, they will.
There are many ways to do that. They can do another secondary,
and if the share price increases substantially I am sure they will do that. They can partner MC-4232.
They will need to that anyway at some point. A blood pressure medication need a big pharma for partnering. They can They can partner MC-1 for ROW, etc.

If I were even dumber than I am I would point out that your arguments do not support your belief of partnering MC-1 in USA.
But since I am way overweight in the stock, and has no intention to increase that even at this ridiculous price, my interest is the stock price increase.

Belief tht Medicure soon partner MC-1 potentialy increase
the share price. Although I believe that the current share price also indicates that nobody really believes that anymore.
So I have no intention to dissuade anybody about believing that partnering is imminent. Of course I
Dunno
anything anyway.

[daved]

I bought MCU this morning, drbio,dunno and crs

The P3 trial for MC1 will be very short compared to most and it looks like an 85%+ probability. The P2 trial was big and nothing changes for the P3.

I like the fact that the recent dilution was oversold.

I expect Merck to pick up the option to market the Aggrostat/MC1 combo but it's not neccessary.

The diabetes indication addresses a large market.

I get ongoing revenue, 45 mil in cash and lots of irons in the fire for my fully diluted (at 1.7/sh) 158 mil cap.

Dave